3 results on atopic dermatitis
Approved WMOCompleted
To explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of LOU064 over a treatment period of 4 weeks in a cohort of subjects with atopic dermatitis.
Approved WMOCompleted
Primair1. Assessment of the pharmacological activity of BAY·1834845 and BAY 1830839 on IMQ induced skin inflammation compared to placebo (prednisolone serves as active control), as quantified by laser speckle contrast imaging (LSCI, perfusion/basal…
Approved WMOCompleted
The primary objective of the study is to reject the Null hypothesis: A 7 to 21 day therapy with moxifloxacin, 400 mg once daily is more than 10 % less effective than a 7 to 21 day therapy with piperacillin/tazobactam three times daily possibly…